Exact Mass: 451.2642
Exact Mass Matches: 451.2642
Found 415 metabolites which its exact mass value is equals to given mass value 451.2642,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
Cabergoline
Cabergoline is only found in individuals that have used or taken this drug. It is a long-acting dopamine agonist and prolactin inhibitor. It is used to treat hyperprolactinemic disorders and Parkinsonian Syndrome. Cabergoline possesses potent agonist activity on dopamine D2 receptors. The dopamine D2 receptor is a 7-transmembrane G-protein coupled receptor associated with Gi proteins. In lactotrophs, stimulation of dopamine D2 causes inhibition of adenylyl cyclase, which decreases intracellular cAMP concentrations and blocks IP3-dependent release of Ca2+ from intracellular stores. Decreases in intracellular calcium levels may also be brought about via inhibition of calcium influx through voltage-gated calcium channels, rather than via inhibition of adenylyl cyclase. Additionally, receptor activation blocks phosphorylation of p42/p44 MAPK and decreases MAPK/ERK kinase phosphorylation. Inhibition of MAPK appears to be mediated by c-Raf and B-Raf-dependent inhibition of MAPK/ERK kinase. Dopamine-stimulated growth hormone release from the pituitary gland is mediated by a decrease in intracellular calcium influx through voltage-gated calcium channels rather than via adenylyl cyclase inhibition. Stimulation of dopamine D2 receptors in the nigrostriatal pathway leads to improvements in coordinated muscle activity in those with movement disorders. Cabergoline is a long-acting dopamine receptor agonist with a high affinity for D2 receptors. Receptor-binding studies indicate that cabergoline has low affinity for dopamine D1, alpha1,- and alpha2- adrenergic, and 5-HT1- and 5-HT2-serotonin receptors. G - Genito urinary system and sex hormones > G02 - Other gynecologicals > G02C - Other gynecologicals > G02CB - Prolactine inhibitors D002491 - Central Nervous System Agents > D018726 - Anti-Dyskinesia Agents > D000978 - Antiparkinson Agents N - Nervous system > N04 - Anti-parkinson drugs > N04B - Dopaminergic agents > N04BC - Dopamine agonists D018377 - Neurotransmitter Agents > D015259 - Dopamine Agents > D018491 - Dopamine Agonists C78272 - Agent Affecting Nervous System > C38149 - Antiparkinsonian Agent C78272 - Agent Affecting Nervous System > C66884 - Dopamine Agonist Cabergoline is an ergot derived-dopamine D2-like receptor agonist that has high affinity for D2, D3, and 5-HT2B receptors (Ki=0.7, 1.5, and 1.2, respectively).
Cytochalasin Opho
Cytochalasin Opho is a mycotoxin produced by Phomopsis sp Mycotoxin production by Phomopsis species
14alpha-Hydroxypaxilline
14alpha-Hydroxypaxilline is a metabolite from Penicillium paxilli. Also identified chromatographically in Acremonium lolii. Metabolite from Penicillium paxilliand is) also identified chromatographically in Acremonium lolii
LysoPE(16:1(9Z)/0:0)
LysoPE(16:1(9Z)/0:0) is a lysophosphatidylethanolamine or a lysophospholipid. The term lysophospholipid (LPL) refers to any phospholipid that is missing one of its two O-acyl chains. Thus, LPLs have a free alcohol in either the sn-1 or sn-2 position. The prefix lyso- comes from the fact that lysophospholipids were originally found to be hemolytic however it is now used to refer generally to phospholipids missing an acyl chain. LPLs are usually the result of phospholipase A-type enzymatic activity on regular phospholipids such as phosphatidylcholine or phosphatidic acid, although they can also be generated by the acylation of glycerophospholipids or the phosphorylation of monoacylglycerols. Some LPLs serve important signaling functions such as lysophosphatidic acid. Lysophosphatidylethanolamines (LPEs) can function as plant growth regulators with several diverse uses. (LPEs) are approved for outdoor agricultural use to accelerate ripening and improve the quality of fresh produce. They are also approved for indoor use to preserve stored crops and commercial cut flowers. As a breakdown product of phosphatidylethanolamine (PE), LPE is present in cells of all organisms. [HMDB] LysoPE(16:1(9Z)/0:0) is a lysophosphatidylethanolamine or a lysophospholipid. The term lysophospholipid (LPL) refers to any phospholipid that is missing one of its two O-acyl chains. Thus, LPLs have a free alcohol in either the sn-1 or sn-2 position. The prefix lyso- comes from the fact that lysophospholipids were originally found to be hemolytic however it is now used to refer generally to phospholipids missing an acyl chain. LPLs are usually the result of phospholipase A-type enzymatic activity on regular phospholipids such as phosphatidylcholine or phosphatidic acid, although they can also be generated by the acylation of glycerophospholipids or the phosphorylation of monoacylglycerols. Some LPLs serve important signaling functions such as lysophosphatidic acid. Lysophosphatidylethanolamines (LPEs) can function as plant growth regulators with several diverse uses. (LPEs) are approved for outdoor agricultural use to accelerate ripening and improve the quality of fresh produce. They are also approved for indoor use to preserve stored crops and commercial cut flowers. As a breakdown product of phosphatidylethanolamine (PE), LPE is present in cells of all organisms.
LysoPE(0:0/16:1(9Z))
LysoPE(0:0/16:1(9Z)) is a lysophosphatidylethanolamine or a lysophospholipid. The term lysophospholipid (LPL) refers to any phospholipid that is missing one of its two O-acyl chains. Thus, LPLs have a free alcohol in either the sn-1 or sn-2 position. The prefix lyso- comes from the fact that lysophospholipids were originally found to be hemolytic however it is now used to refer generally to phospholipids missing an acyl chain. LPLs are usually the result of phospholipase A-type enzymatic activity on regular phospholipids such as phosphatidylcholine or phosphatidic acid, although they can also be generated by the acylation of glycerophospholipids or the phosphorylation of monoacylglycerols. Some LPLs serve important signaling functions such as lysophosphatidic acid. Lysophosphatidylethanolamines (LPEs) can function as plant growth regulators with several diverse uses. (LPEs) are approved for outdoor agricultural use to accelerate ripening and improve the quality of fresh produce. They are also approved for indoor use to preserve stored crops and commercial cut flowers. As a breakdown product of phosphatidylethanolamine (PE), LPE is present in cells of all organisms. [HMDB] LysoPE(0:0/16:1(9Z)) is a lysophosphatidylethanolamine or a lysophospholipid. The term lysophospholipid (LPL) refers to any phospholipid that is missing one of its two O-acyl chains. Thus, LPLs have a free alcohol in either the sn-1 or sn-2 position. The prefix lyso- comes from the fact that lysophospholipids were originally found to be hemolytic however it is now used to refer generally to phospholipids missing an acyl chain. LPLs are usually the result of phospholipase A-type enzymatic activity on regular phospholipids such as phosphatidylcholine or phosphatidic acid, although they can also be generated by the acylation of glycerophospholipids or the phosphorylation of monoacylglycerols. Some LPLs serve important signaling functions such as lysophosphatidic acid. Lysophosphatidylethanolamines (LPEs) can function as plant growth regulators with several diverse uses. (LPEs) are approved for outdoor agricultural use to accelerate ripening and improve the quality of fresh produce. They are also approved for indoor use to preserve stored crops and commercial cut flowers. As a breakdown product of phosphatidylethanolamine (PE), LPE is present in cells of all organisms.
4-Hydroxyvalsartan
4-Hydroxyvalsartan is only found in individuals that have used or taken Valsartan. 4-Hydroxyvalsartan is a metabolite of Valsartan. 4-hydroxyvalsartan belongs to the family of Biphenyltetrazoles and Derivatives. These are organic compounds containing a biphenyl attached to a tetrazole. A carbon atom of the biphenyl moiety is boned to a carbon or the nitrogen atom of the tetrazole moiety.
Enterocin 900
Enterocin 900 is found in fruits. Enterocin 900 is produced by Enterococcus faecium BFE900 from black olives.
(10E,12E,14E)-9-Hydroxy-16-oxooctadeca-10,12,14-trienoylcarnitine
(10E,12E,14E)-9-hydroxy-16-oxooctadeca-10,12,14-trienoylcarnitine is an acylcarnitine. More specifically, it is an (10E,12E,14E)-9-hydroxy-16-oxooctadeca-10,12,14-trienoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (10E,12E,14E)-9-hydroxy-16-oxooctadeca-10,12,14-trienoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine (10E,12E,14E)-9-hydroxy-16-oxooctadeca-10,12,14-trienoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
(10E,12E,14E)-16-Hydroxy-9-oxooctadeca-10,12,14-trienoylcarnitine
(10E,12E,14E)-16-hydroxy-9-oxooctadeca-10,12,14-trienoylcarnitine is an acylcarnitine. More specifically, it is an (10E,12E,14E)-16-hydroxy-9-oxooctadeca-10,12,14-trienoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (10E,12E,14E)-16-hydroxy-9-oxooctadeca-10,12,14-trienoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine (10E,12E,14E)-16-hydroxy-9-oxooctadeca-10,12,14-trienoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
N-Arachidonoyl Phenylalanine
N-arachidonoyl phenylalanine belongs to the class of compounds known as N-acylamides. These are molecules characterized by a fatty acyl group linked to a primary amine by an amide bond. More specifically, it is an Arachidonic acid amide of Phenylalanine. It is believed that there are more than 800 types of N-acylamides in the human body. N-acylamides fall into several categories: amino acid conjugates (e.g., those acyl amides conjugated with amino acids), neurotransmitter conjugates (e.g., those acylamides conjugated with neurotransmitters), ethanolamine conjugates (e.g., those acylamides conjugated to ethanolamine), and taurine conjugates (e.g., those acyamides conjugated to taurine). N-Arachidonoyl Phenylalanine is an amino acid conjugate. N-acylamides can be classified into 9 different categories depending on the size of their acyl-group: 1) short-chain N-acylamides; 2) medium-chain N-acylamides; 3) long-chain N-acylamides; and 4) very long-chain N-acylamides; 5) hydroxy N-acylamides; 6) branched chain N-acylamides; 7) unsaturated N-acylamides; 8) dicarboxylic N-acylamides and 9) miscellaneous N-acylamides. N-Arachidonoyl Phenylalanine is therefore classified as a long chain N-acylamide. N-acyl amides have a variety of signaling functions in physiology, including in cardiovascular activity, metabolic homeostasis, memory, cognition, pain, motor control and others (PMID: 15655504). N-acyl amides have also been shown to play a role in cell migration, inflammation and certain pathological conditions such as diabetes, cancer, neurodegenerative disease, and obesity (PMID: 23144998; PMID: 25136293; PMID: 28854168).N-acyl amides can be synthesized both endogenously and by gut microbiota (PMID: 28854168). N-acylamides can be biosynthesized via different routes, depending on the parent amine group. N-acyl ethanolamines (NAEs) are formed via the hydrolysis of an unusual phospholipid precursor, N-acyl-phosphatidylethanolamine (NAPE), by a specific phospholipase D. N-acyl amino acids are synthesized via a circulating peptidase M20 domain containing 1 (PM20D1), which can catalyze the bidirectional the condensation and hydrolysis of a variety of N-acyl amino acids. The degradation of N-acylamides is largely mediated by an enzyme called fatty acid amide hydrolase (FAAH), which catalyzes the hydrolysis of N-acylamides into fatty acids and the biogenic amines. Many N-acylamides are involved in lipid signaling system through interactions with transient receptor potential channels (TRP). TRP channel proteins interact with N-acyl amides such as N-arachidonoyl ethanolamide (Anandamide), N-arachidonoyl dopamine and others in an opportunistic fashion (PMID: 23178153). This signaling system has been shown to play a role in the physiological processes involved in inflammation (PMID: 25136293). Other N-acyl amides, including N-oleoyl-glutamine, have also been characterized as TRP channel antagonists (PMID: 29967167). N-acylamides have also been shown to have G-protein-coupled receptors (GPCRs) binding activity (PMID: 28854168). The study of N-acylamides is an active area of research and it is likely that many novel N-acylamides will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered for these molecules.
Cenisertib
Dibekacin
Dihydroxylysinonorleucine
Chasmanine
A diterpene alkaloid with formula C25H41NO6 that is isolated from several Aconitum species.
20-ethyl-1,14-dimethoxy-4-methyl-7,8-methylenedioxy-1alpha,5R,6beta,9S,14alpha,16beta-aconitane-6,10,16-triol|deacetylelasine
methyl beta-fucopyranosyl(1->4)-beta-saccharosaminopyranosyl(1->4)-beta-digitoxopyranoside
2-(5R,15S-dihydroxyeicosanoylamino)ethanesulfonic acid
(2S,4aR,4bR,6aS,12bS,12cS,14aS)-4a-demethylpaspaline-4a-carboxylic acid
(15aR)-17c-hydroxy-(15ar,19acC13)-16,7,8,9,55,6-hexahydro-15aH-10-aza-1(2,9a)-dibenzofurana-5(1,3)-pyrimidina-cyclotridecaphane-2t,12t-diene-4,11-dione|3alpha-hydroxy-21,25-methanediyl-3-deoxo-lunarine|Alkaloid LBZ|alkaloid LBZ (Lunaria)|N21,N25-methanediyl-lunarinol-II
Ala Ala Lys Tyr
Ala Ala Tyr Lys
Ala Phe Lys Ser
Ala Phe Ser Lys
Ala His Lys Pro
Ala His Pro Lys
Ala His Pro Gln
Ala His Gln Pro
Ala Lys Ala Tyr
Ala Lys Phe Ser
Ala Lys His Pro
Ala Lys Pro His
Ala Lys Ser Phe
Ala Lys Tyr Ala
Ala Pro His Lys
Ala Pro His Gln
Ala Pro Lys His
Ala Pro Gln His
Ala Gln His Pro
Ala Gln Pro His
Ala Ser Phe Lys
Ala Ser Lys Phe
Ala Tyr Ala Lys
Ala Tyr Lys Ala
Phe Ala Lys Ser
Phe Ala Ser Lys
Phe Gly Lys Thr
Phe Gly Thr Lys
Phe Lys Ala Ser
Phe Lys Gly Thr
Phe Lys Ser Ala
Phe Lys Thr Gly
Phe Ser Ala Lys
Phe Ser Lys Ala
Phe Thr Gly Lys
Phe Thr Lys Gly
Gly Phe Lys Thr
Gly Phe Thr Lys
Gly Gly Arg Tyr
Gly Gly Tyr Arg
Gly Lys Phe Thr
Gly Lys Thr Phe
Gly Arg Gly Tyr
Gly Arg Tyr Gly
Gly Thr Phe Lys
Gly Thr Lys Phe
Gly Tyr Gly Arg
Gly Tyr Arg Gly
His Ala Lys Pro
His Ala Pro Lys
His Ala Pro Gln
His Ala Gln Pro
His Lys Ala Pro
His Lys Pro Ala
His Pro Ala Lys
His Pro Ala Gln
His Pro Lys Ala
His Pro Gln Ala
His Gln Ala Pro
His Gln Pro Ala
Lys Ala Ala Tyr
Lys Ala Phe Ser
Lys Ala His Pro
Lys Ala Pro His
Lys Ala Ser Phe
Lys Ala Tyr Ala
Lys Phe Ala Ser
Lys Phe Gly Thr
Lys Phe Ser Ala
Lys Phe Thr Gly
Lys Gly Phe Thr
Lys Gly Thr Phe
Lys His Ala Pro
Lys His Pro Ala
Lys Pro Ala His
Lys Pro His Ala
Lys Ser Ala Phe
Lys Ser Phe Ala
Lys Thr Phe Gly
Lys Thr Gly Phe
Lys Tyr Ala Ala
Pro Ala His Lys
Pro Ala His Gln
Pro Ala Lys His
Pro Ala Gln His
Pro His Ala Lys
Pro His Ala Gln
Pro His Lys Ala
Pro His Gln Ala
Pro Lys Ala His
Pro Lys His Ala
Pro Gln Ala His
Pro Gln His Ala
Gln Ala His Pro
Gln Ala Pro His
Gln His Ala Pro
Gln His Pro Ala
Gln Pro Ala His
Gln Pro His Ala
Arg Gly Gly Tyr
Arg Gly Tyr Gly
Arg Tyr Gly Gly
Ser Ala Phe Lys
Ser Ala Lys Phe
Ser Phe Ala Lys
Ser Phe Lys Ala
Ser Lys Ala Phe
Ser Lys Phe Ala
Thr Phe Gly Lys
Thr Phe Lys Gly
Thr Gly Phe Lys
Thr Gly Lys Phe
Thr Lys Phe Gly
Thr Lys Gly Phe
Tyr Ala Ala Lys
Tyr Ala Lys Ala
Tyr Gly Gly Arg
Tyr Gly Arg Gly
Tyr Lys Ala Ala
Tyr Arg Gly Gly
Platelet-activating factor
PC(O-14:1/0:0)
PC(P-14:0/0:0)
dibekacin
J - Antiinfectives for systemic use > J01 - Antibacterials for systemic use > J01G - Aminoglycoside antibacterials A kanamycin that is kanamycin B lacking the 3- and 4-hydroxy groups on the 2,6-diaminosugar ring. S - Sensory organs > S01 - Ophthalmologicals > S01A - Antiinfectives > S01AA - Antibiotics C784 - Protein Synthesis Inhibitor > C2363 - Aminoglycoside Antibiotic D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents C254 - Anti-Infective Agent > C258 - Antibiotic
4-Hydroxyvalsartan
Cytochalasin Opho
Enterocin 900
7-Hydroxypaxilline
4-Cyano-4-biphenylyl 4-(trans-4-pentylcyclohexyl)benzoate
3-(2H-Benzotriazolyl)-5-(1,1-di-methylethyl)-4-hydroxy-benzenepropanoic acid octyl esters
n-2-nitrophenylsulfenyl-l-valine dicyclohexylammonium salt
1-Octadecanaminium, N,N-bis(2-hydroxyethyl)-N-methyl-, bromide
Cenisertib
C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C61074 - Serine/Threonine Kinase Inhibitor C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor Cenisertib (AS-703569) is an ATP-competitive multi-kinase inhibitor that blocks the activity of Aurora-kinase-A/B, ABL1, AKT, STAT5 and FLT3. Cenisertib induces major growth-inhibitory effects by blocking the activity of several different molecular targets in neoplastic mast cells (MC). Cenisertib inhibits tumor growth in xenograft models of pancreatic, breast, colon, ovarian, and lung tumors and leukemia[1][2][3].
2-(4-Dimethylaminophenyl)-5-(4-methyl-1-piperazinyl)-2,5-BI-benzimidazole
Sanfetrinem cilexetil
D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D007769 - Lactams C254 - Anti-Infective Agent > C258 - Antibiotic > C260 - Beta-Lactam Antibiotic
2-(butan-2-ylamino)-N-[4-[5-[[2-(butan-2-ylamino)acetyl]amino]-1,3-benzoxazol-2-yl]phenyl]acetamide
N-(4-{[(3s)-3-(Dimethylamino)pyrrolidin-1-Yl]carbonyl}phenyl)-5-Fluoro-4-[2-Methyl-1-(1-Methylethyl)-1h-Imidazol-5-Yl]pyrimidin-2-Amine
[(3S)-3,4-di(hexanoyloxy)butyl]-[2-(trimethylazaniumyl)ethoxy]phosphinate
1-(9Z-hexadecenoyl)-sn-glycero-3-phosphoethanolamine
(2S)-3-(4-hydroxyphenyl)-2-[(4E,6E,8E,10E,12E)-2,6,10,12-tetramethyl-3-oxotetradeca-4,6,8,10,12-pentaenamido]propanoate
a 1-acyl-sn-glycero-3-phosphoethanolamine (n-C16:1)
a 2-acyl-sn-glycero-3-phosphoethanolamine (n-C16:1)
[(2R)-3-[2-aminoethoxy(hydroxy)phosphoryl]oxy-2-hydroxypropyl] hexadec-7-enoate
[(2R)-1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-hydroxypropan-2-yl] (E)-hexadec-11-enoate
6-Amino-2-[2-[(5-amino-1-carboxy-4-hydroxypentyl)amino]-2-(1-carboxypentyl)hydrazinyl]-5-hydroxyhexanoic acid
(10E,12E,14E)-9-Hydroxy-16-oxooctadeca-10,12,14-trienoylcarnitine
(10E,12E,14E)-16-Hydroxy-9-oxooctadeca-10,12,14-trienoylcarnitine
2-(butylamino)-N-[4-[5-[[2-(butylamino)-1-oxoethyl]amino]-1,3-benzoxazol-2-yl]phenyl]acetamide
N-{3-[(5-cyclopropyl-2-{[3-methyl-1-(2,2,2-trifluoroethyl)-1H-pyrazol-4-yl]amino}pyrimidin-4-yl)amino]propyl}cyclobutanecarboxamide
7,7-dimethyl-1-(4-methylphenyl)-N-[3-(4-morpholinyl)propyl]-2,5-dioxo-6,8-dihydroquinoline-3-carboxamide
2-(trimethylsilyl)ethyl 2-acetamido-2-deoxy-3-O-(beta-D-tyvelopyranosyl)-beta-D-galactopyranoside
(11)-Cytochalasa-6(12),13-diene-1,21-dione-7,9-dihydroxy-16,18-dimethyl-lO-phenyl-(7S*,13E,16S*,18R*,19R*)
1-[(1S)-2-[(3-fluorophenyl)methyl]-1-(hydroxymethyl)-7-methoxy-1-spiro[3,9-dihydro-1H-pyrido[3,4-b]indole-4,4-piperidine]yl]ethanone
(2R,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-8-(3-methylbut-1-ynyl)-2-[[methyl(5-pyrimidinylmethyl)amino]methyl]-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one
(2S,3S,3aR,9bR)-3-(hydroxymethyl)-6-oxo-N-(2-piperidin-1-ylethyl)-1-(pyridin-2-ylmethyl)-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide
(2S,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-8-(3-methylbut-1-ynyl)-2-[[methyl(5-pyrimidinylmethyl)amino]methyl]-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one
(2S,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-8-(3-methylbut-1-ynyl)-2-[[methyl(5-pyrimidinylmethyl)amino]methyl]-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one
(2S,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-8-(3-methylbut-1-ynyl)-2-[[methyl(5-pyrimidinylmethyl)amino]methyl]-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one
(2R,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-8-(3-methylbut-1-ynyl)-2-[[methyl(5-pyrimidinylmethyl)amino]methyl]-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one
(2S,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-8-(3-methylbut-1-ynyl)-2-[[methyl(5-pyrimidinylmethyl)amino]methyl]-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one
(2R,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-8-(3-methylbut-1-ynyl)-2-[[methyl(5-pyrimidinylmethyl)amino]methyl]-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one
(2R,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-8-(3-methylbut-1-ynyl)-2-[[methyl(5-pyrimidinylmethyl)amino]methyl]-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one
(2R,3R,3aS,9bS)-3-(hydroxymethyl)-6-oxo-N-(2-piperidin-1-ylethyl)-1-(pyridin-2-ylmethyl)-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide
1-[(3aS,4R,9bR)-4-(hydroxymethyl)-8-(2-methoxyphenyl)-5-methyl-3,3a,4,9b-tetrahydro-2H-pyrrolo[3,2-c]quinolin-1-yl]-2-(4-morpholinyl)ethanone
1-[(1R)-2-[(3-fluorophenyl)methyl]-1-(hydroxymethyl)-7-methoxy-1-spiro[3,9-dihydro-1H-pyrido[3,4-b]indole-4,4-piperidine]yl]ethanone
(2-fluorophenyl)-[(1R)-1-(hydroxymethyl)-7-methoxy-2,9-dimethyl-1-spiro[1,3-dihydropyrido[3,4-b]indole-4,4-piperidine]yl]methanone
(4-fluorophenyl)-[(1S)-1-(hydroxymethyl)-7-methoxy-1,9-dimethyl-2-spiro[1,3-dihydropyrido[3,4-b]indole-4,4-piperidine]yl]methanone
1-[(1R)-1-[(4-fluorophenyl)methyl]-1-(hydroxymethyl)-7-methoxy-9-methyl-2-spiro[1,3-dihydropyrido[3,4-b]indole-4,3-azetidine]yl]-1-propanone
(4-fluorophenyl)-[(1R)-1-(hydroxymethyl)-7-methoxy-1,9-dimethyl-2-spiro[1,3-dihydropyrido[3,4-b]indole-4,4-piperidine]yl]methanone
1-[(1S)-1-[(4-fluorophenyl)methyl]-1-(hydroxymethyl)-7-methoxy-9-methyl-2-spiro[1,3-dihydropyrido[3,4-b]indole-4,3-azetidine]yl]-1-propanone
1-(4-amino-1,2,5-oxadiazol-3-yl)-5-[(dipropylamino)methyl]-N-[(E)-[(E)-2-methyl-3-phenylprop-2-enylidene]amino]triazole-4-carboxamide
[3-[2-aminoethoxy(hydroxy)phosphoryl]oxy-2-hydroxypropyl] (Z)-hexadec-9-enoate
2-aminoethyl [3-[(Z)-heptadec-9-enoxy]-2-hydroxypropyl] hydrogen phosphate
[2-hydroxy-3-[(Z)-tetradec-9-enoxy]propyl] 2-(trimethylazaniumyl)ethyl phosphate
[2-hydroxy-3-[(Z)-tridec-9-enoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(Z)-tridec-9-enoxy]propan-2-yl] propanoate
3-Hydroxy-2-(2-hydroxydodecanoylamino)decane-1-sulfonic acid
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(Z)-tetradec-9-enoxy]propan-2-yl] acetate
[1-acetyloxy-3-[2-aminoethoxy(hydroxy)phosphoryl]oxypropan-2-yl] (Z)-tridec-9-enoate
[(2R)-3-[2-aminoethoxy(hydroxy)phosphoryl]oxy-2-hydroxypropyl] (E)-hexadec-9-enoate
[(2R)-3-[2-aminoethoxy(hydroxy)phosphoryl]oxy-2-hydroxypropyl] (E)-hexadec-7-enoate
2-[hydroxy-[(E)-3-hydroxy-2-(propanoylamino)tridec-4-enoxy]phosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[(E)-3-hydroxy-2-(octanoylamino)oct-4-enoxy]phosphoryl]oxyethyl-trimethylazanium
2-[[(E)-2-(butanoylamino)-3-hydroxydodec-4-enoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[[(E)-2-acetamido-3-hydroxytetradec-4-enoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[(E)-3-hydroxy-2-(pentanoylamino)undec-4-enoxy]phosphoryl]oxyethyl-trimethylazanium
2-[[(E)-2-(hexanoylamino)-3-hydroxydec-4-enoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[[(E)-2-(heptanoylamino)-3-hydroxynon-4-enoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
Cabergoline
G - Genito urinary system and sex hormones > G02 - Other gynecologicals > G02C - Other gynecologicals > G02CB - Prolactine inhibitors D002491 - Central Nervous System Agents > D018726 - Anti-Dyskinesia Agents > D000978 - Antiparkinson Agents N - Nervous system > N04 - Anti-parkinson drugs > N04B - Dopaminergic agents > N04BC - Dopamine agonists D018377 - Neurotransmitter Agents > D015259 - Dopamine Agents > D018491 - Dopamine Agonists C78272 - Agent Affecting Nervous System > C38149 - Antiparkinsonian Agent C78272 - Agent Affecting Nervous System > C66884 - Dopamine Agonist Cabergoline is an ergot derived-dopamine D2-like receptor agonist that has high affinity for D2, D3, and 5-HT2B receptors (Ki=0.7, 1.5, and 1.2, respectively).
N-[3-(dimethylamino)propyl]-N-(ethylcarbamoyl)-7-prop-2-enyl-6,6a,8,9,10,10a-hexahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide
1-(10E-undecenyl)-2-acetyl-sn-glycero-3-phosphocholine
beta-D-Tyvp-(1->3)-beta-D-GalpNAc-OCH2CH2SiMe3
An amino disaccharide consisting of 2-(trimethylsilyl)ethyl N-acetyl-beta-D-galactosaminide having a beta-D-tyvelosyl residue attached at the 3-position.
PE(16:1)
Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved
PE(15:1)
Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved
AMPK-IN-3
AMPK-IN-3 (compound 67) is a potent and selective AMPK inhibitor with IC50s of 60.7, 107 and 3820 nM for AMPK (α2), AMPK (α1) and KDR, respectively. AMPK-IN-3 inhibits AMPK does not affect cell viability or cause significant cytotoxicity in K562 cells. AMPK-IN-3 can be used in study of cancer[1].
